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Abstract The heterogeneity of human breast cancer has
been well described at the morphological, molecular, and
genomic levels. This heterogeneity presents one of the
greatest obstacles in the effective treatment of breast cancer
since the distinct forms of breast cancer that reflect distinct
mechanisms of disease will require distinct therapies.
Although mouse models of cancer have traditionally been
used to simplify the study of human disease, we suggest
that there are opportunities to also model the complexity
and heterogeneity of human cancer. Here, we illustrate the
similarities of mouse models to the human condition in the
heterogeneity of both pathologies and gene expression. We
then provide an illustration of the potential of gene
expression analysis methods when used in conjunction
with current treatment options to model individualized
therapeutic regimes.
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Heterogeneity in human cancer
A key and dominant feature of human cancer, including
breast cancer, is the heterogeneity evident in the disease.
Various studies now point to the identification of multiple
distinct forms of breast cancer. This presents a problem in
both understanding the mechanisms of progression and in
developing therapeutic options. The development of human
breast cancer results in tumors with a wide array of
morphological subtypes, starting with the broad classifica-
tion as invasive ductal cancinoma or invasive lobular
carcinomas. With examination of biomarkers such as ER
and PR status, these broad classifications may be further
broken down into subgroups. Addition of other markers
allows further classification, ultimately resulting in a
number of heterogeneous histological subtypes. Indeed,
unlike chronic myeloid leukemia, where the vast majority
of tumors are quite similar due to the BCR/ABL1
translocation [1], breast cancer is now recognized to be a
diverse collection of disease states.
A hallmark of human cancer is genetic complexity,
which reflects the mutations that give rise to the tumor
phenotype. This is especially true for breast cancer where a
number of different mutations are commonly observed,
such as HER2 (Neu, ErbB2) amplification and over-
expression in 20–30% of tumors [2–4]. Amplification of
other genes is also observed including amplification of Myc
in 15% of breast cancers [5]. In addition to these
spontaneous mutations, 10% of breast cancer is due to
inherited mutations in genes such as BRCA1/BRCA2 [6–
8]. Given the wide number of mutations involved in breast
cancer, recent large-scale DNA sequencing efforts have
illustrated the genetic complexity of cancer, revealing many
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types of alterations that can distinguish tumor subtypes [9–
12]. In particular, the study by Wood et al. characterized
several mutations that occurred in a large majority of the
tumors and a large number of additional mutations that
arose in smaller subsets of tumors, illustrating the hetero-
geneity present within mutations associated with breast
cancer [12]. Together, the genetic alterations that underlie
breast cancer and the resulting histological subtypes
illustrate the heterogeneous nature of the disease.
The array of genetic abnormalities inherent within breast
cancer is also reflected in the complexity of associated gene
expression data. Indeed, initial studies on human breast
cancer using large numbers of samples revealed heteroge-
neity in the tumor samples with subtypes that correlated
with differences in clinical outcome [13]. Subsequent
studies have refined the expression patterns in the large
datasets into predictions for subtypes of breast cancer.
Indeed, these methods have allowed for the generation of
the well-known luminal A, luminal B, basal, ErBB2+ and
normal breast-like classification using an intrinsic method
[14–16], reflecting the concept that the gene expression
data is associated with histological subtypes.
In addition to these methods, recent work has used
signatures of cell signaling pathways to investigate the
pattern of gene expression in a variety of samples [17–20].
This method uses gene expression data from control
samples and pathway-activated samples as the training data
to develop a series of pathway signatures. Through the
development of regression models, a probability score can
then be assigned to subsequent datasets that are examined
using the signature that separates the biological states.
Importantly, for our studies of breast cancer, these genetic
signatures have largely been created in primary human
mammary epithelial cells (HMECs). In order to ensure that
we have constructed signatures for the transcriptional
response to the pathway of interest, RNA is collected
shortly after the expression of the gene of interest [17]. For
example, the expression of an activated RAS gene in
HMECs via an adenoviral vector generates a gene
expression pattern quite distinct from that in cells infected
with a control viral vector or cells expressing a different
oncogene. This signature can then be applied to additional
samples in separate tumor datasets, generating probability
scores for individual samples sharing the RAS gene
expression profile [17]. As an example, two breast cancer
datasets (GSE4922 [21] and GSE15852), were examined
using a collection of pathway signatures. The resulting
pathway probabilities were then clustered (unsupervised
hierarchical clustering) to reveal patterns of pathway
activity that could be presented as a heat map. Such an
analysis revealed a number of distinct clusters with differ-
ences in pathway probability (Fig. 1). This approach serves
to provide detailed information about the status of pathway
activation. By clustering this data, human breast cancer can
then be divided into various subgroups based on the gene
expression data. Since other works have demonstrated a
link between the prediction of pathway activity and
prediction of sensitivity to drugs targeting the pathway
[17, 22], these predictions present a unique opportunity for
therapeutic options. Essentially, we have generated predic-
tions for individual tumors for the status of various
pathways, which are in some cases the underlying
mechanism of the heterogeneous disease. Many of these
pathways can be linked directly to therapeutic opportuni-
ties, suggesting that these methods could be used to
generate individualized therapies.
Heterogeneity of breast cancer is recapitulated in mouse
models
The generation of transgenic mouse models of breast cancer
began with the creation of mice expressing Myc under the
control of the Mouse Mammary Tumor Virus (MMTV)
promoter/enhancer [23]. Since that time, many oncogenes
have been placed under the control of MMTV with various
types of resulting mammary tumors. Interestingly, many of
these transgenic mice induce tumors that have a distinctive
pathology that is dependent upon the initiating oncogene
[24]. Specifically, this work illustrated that for mice
overexpressing Ras, Neu or Myc there was a characteristic
phenotype in the resulting tumors consistent with the notion
that these tumors have been initiated by a dominant
oncogene. Conversely, other mouse models of breast cancer
are known to result in varied morphological patterns, more
analogous to the human condition. For instance, mammary
tumors induced through expression of Wnt or members of
the Wnt signaling pathway, are known to have a wide range
of histological patterns in the resulting tumors [25]. This is
also true for MET-induced tumors which produced tumors
that were found to have a number of pathologies including
papillary, scirrhous, solid nodular, adenosquamous, and
spindle cell [26]. Other models are also known to result in
tumors with varied morphology, including the Polyoma
Virus Middle T model, with six well characterized
phenotypes [27]. Taken together, these various models
suggest that a careful examination of the histological
subtypes of tumors in a given experiment is a critical
component of evaluating the utility of the model.
With these studies in mind, we have recently described
work with transgenic mice overexpressing various Myc
alleles under the control of the MMTV promoter [28].
While we noted a distinctive phenotype for each of the Myc
alleles composing approximately 40% of the tumor type for
each strain, by closely examining a large number of tumors
(>350), we noted substantial heterogeneity in the Myc
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models. The histological types we observed ranged from
microacinar and papillary as the dominant morphologies, to
epithelial, to mesenchymal transition (EMT), squamous,
adenocarcinomas and tumors with mixed lineages. This
suggested that while Myc does preferentially induce a
distinct phenotype, there is also significant heterogeneity.
To examine the heterogeneity of this model system, tumors
from each histological subtype were examined through
gene expression analysis. Unsupervised hierarchical clus-
tering of this microarray data revealed that there were a
number of distinct groups of samples [28]. Importantly,
these subgroups of samples were clustered into groups
based on gene expression patterns that corresponded with
the histological classifications. While not surprising that the
histological characteristics of a tumor are reflected in the
transcriptional changes, it is important to note the hetero-
geneity of the various tumors. Interestingly, when these
various classes of tumors were compared to a survey of
mouse mammary cancers [29], it was noted that the various
classes fit with other tumor models. As an example, the
EMT tumors clustered with the p53-/- and DMBA tumors.
In the description of the MMTV–MET tumors [26], it was
also observed that there were heterogeneous tumor pop-
ulations at the gene expression level and that the EMT
tumors clustered together with the p53-/- tumors. Together,
these findings illustrate the importance of examining both
histological variation and gene expression patterns.
To further dissect the heterogeneity of the Myc-initiated
mouse mammary tumors, but do so with information that
provides a basis for understanding functional distinctions in
subgroups, we applied the various pathway signatures to
the collection of tumors. This analysis revealed that the
same histological subtypes were also able to be distin-
guished based on the higher order structure within the data.
Compared with the unsupervised clustering, this resulted in
similar patterns but also revealed additional information.
For instance, this analysis illustrated that the Ras pathway
was highly activated in EMT tumors but was not likely to
be activated in microacinar tumors, providing information
to allow one to decipher the patterns of gene expression
data. Together with the histological data, this has allowed
for a more informative characterization of the various
subtypes of Myc-induced mammary tumors [28]. Impor-























Fig. 1 Signaling pathway prob-
ability in human tumors. Human
breast cancer gene expression
data from previous studies were
downloaded (GSE4922 and
GSE15852), normalized and the
two datasets were merged to-
gether using the Affymetrix
housekeeping genes to stan-
dardize between batches. The
combined dataset was then ex-
amined for patterns of signaling
pathway activation. Upon gen-
erating signaling pathway acti-
vation probabilities, the data
was clustered and the resulting
heat map is shown for the path-
ways indicated at the right. For
a given pathway, blue represents
a low probability of pathway
activation while red represents a
high probability of activation.
These datasets also included
clinical status for the grade of
the tumor (1, 2, 3) and in one
dataset normal breast samples
were included (GSE15852).
This additional clinical data is
shown in the legend above the
heat map. Using only signaling
pathway probabilities, the het-
erogeneity within human tumors
is readily apparent
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tumor model with human breast cancer, which has revealed
subtypes of human breast cancer that share pathways with
the mouse model, but has also revealed key distinctions.
For example, in Fig. 1 there is a clear correlation between
Myc and Ras in human breast cancer. However, in the Myc-
induced mouse model we reported an inverse correlation
between Myc and Ras [28]. In contrast, in the human
signatures, we note in Fig. 1, that there are subgroups of
cancers with an elevated probability of activation of both
E2F1 and β-catenin (CTNNB1) (BCAT pathway in figure
legend). Interestingly, in the mouse predictions we noted a
shared elevation of E2F1 and β-catenin in a select subtype
of breast cancer, notably in the microacinar tumors. This
association was altered in other tumor types, such as EMT
where E2F1 was low and β-catenin was midrange and in
papillary where E2F1 probability was high while β-catenin
was low. These examples illustrate the utility of using
genomic signatures to compare tumors.
As an important component of mouse models, compar-
isons have been drawn between other mouse model systems
and human breast cancer. Initially through a survey of 13
models of murine breast cancer, comparisons were made in
gene expression patterns using an intrinsic gene expression
signature [29]. This study revealed the relationships
between the various mouse model systems with an intrinsic
gene set, a group of genes that defined the various mouse
models. This analysis revealed the similarities and differ-
ences between the various mouse models of breast cancer,
generating a number of clusters, including normal mam-
mary gland, mesenchymal, basal, luminal, and mixed
groups of tumors [29]. In addition to comparing across
various mouse models, this report also examined the
relation between the models and human breast cancer.
Through unsupervised clustering, they revealed that the
defining features of the human predictions (luminal A,
luminal B, and basal) were maintained in specific mouse
model systems, for instance, key genes from the basal
cluster were shared in several mouse models. However, this
analysis also illustrated that the luminal tumor type was not
tightly related to the various murine tumor models,
although there were genes with similar expression profiles.
In addition, this report uses an intrinsic analysis to compare
the mouse and human tumors, which placed several of the
mouse models together with the luminal tumors, but at the
same time, illustrated the estrogen-receptor-mediated differ-
ences between the model systems and the human tumors.
With this mouse model data as a framework, several recent
papers have then generated gene expression data from
additional models and then compared it to these 13 mouse
model systems [26, 28, 30, 31]. This has provided an
important context to determine how new tumor models
relate to the existing models and to determine what human
tumors they are most similar to. Indeed, the ability to
determine what type of human cancer these mouse models
are most closely related to is a critical component in
characterizing the mouse model tumors at both the level of
gene expression patterns and histological subtypes such as
basal and luminal types. In another approach, we created a
signature of Myc-driven tumors that had an EMT compo-
nent and applied this phenotypic signature to the human
breast cancer gene expression data. This analysis revealed
that triple negative (ER, PR and HER2 negative) breast
MMTV Transgenic






Fig. 2 Theraputic strategy based on signaling pathway profiles. The
design of a proof of the principle experiment where signaling pathway
probabilities guide the use of different drug combinations is shown. A
line of MMTV-based transgenic mice that develop tumors with
demonstrated heterogeneity are used in this scheme. As spontaneous
tumors develop, they are biopsied and their gene expression patterns
are immediately examined. Based on the patterns of signaling pathway
activation, the mice will be grouped into the appropriate therapeutic
option or into a control group. Following treatment with the
individualized predicted therapeutic combinations, the response of
the tumor will be assessed
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cancer had a significant elevation of EMT probability,
identifying this mouse model as one that may be appropri-
ate for examination of potential therapeutic strategies.
Opportunities to explore strategies for individualized
therapy
Based upon a combination of clinical, histological and
genomic data, the goal of current care in breast cancer is to
offer a course of treatment best suited to the individual
patient. One of the greatest challenges for the effective
treatment of this disease is the heterogeneity as we
previously discussed, therefore, spurring the current focus
on individualized medicine. The importance of dissecting
this heterogeneity is best illustrated with the example of the
breast cancer drug trastuzumab. Only a small fraction of all
breast cancer patients benefit from trastuzumab, but with
the use of the HER2 biomarker, trastuzumab becomes an
effective therapy in breast cancer by pre-selecting patients
who might respond [32].
Perhaps the most significant outcome of the genomic
analyses of the mouse mammary tumor models is the
realization that the heterogeneity characteristic of the
human disease is recapitulated in these models. As such,
they have the potential for providing an opportunity to
evaluate the effectiveness of using genomic data to guide
the selection of a therapeutic regimen tailored to individual
mice. There are a number of clear advantages to this
strategy. Firstly, by using a model where we have clearly
defined the genetic heterogeneity, we will be able to make
probability predictions for the therapies for the various
types of tumors that are commonly observed. Secondly, the
relation of the various mouse models to human breast
cancer has been defined genetically. In addition, the mouse
serves as an exceptional experimental system since mam-
mary tumors are readily detected, biopsied, and trans-
planted, and responses to therapy can be measured through
a variety of methods [33]. Finally, in contrast to human
tumors where the standard of care must be maintained, the
mouse model offers an opportunity to test only those
therapeutic compounds with the highest predicted proba-
bility of activity. Given these advantages of the murine
system, coupled with our previous characterization of the
patterns of pathway activation in the Myc tumor model
[28], we have identified therapeutic targets and have begun
an investigation into their efficacy. Our basic experimental
design is to mimic a human trial, where samples are
biopsied, examined for gene expression characteristics and
then randomized into treatment groups (Fig. 2). In addition,
by implanting portions of the biopsy material into addi-
tional recipient mice we are directly able to compare
treatment of the predicted, control and no therapeutic
intervention on a tumor sample. This proof of principal
experiment will demonstrate the utility of the mouse in
modeling individualized breast cancer therapy.
Conclusion
In the near future, examination of genomic data will be an
integral part of directing the therapeutic strategies for
individual breast cancer patients. The dissection of the
complexity of the disease that originates in the heterogene-
ity of human breast cancer is being modeled in mice and
the results that are observed in these model systems will
have direct effects upon the development of individualized
therapeutic opportunities.
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